Arbutus Biopharma

(NASDAQ) ABUS

Current Price$4.05

Market Cap$817.30M

Since IPO (2010)-41%

5 Year+18%

1 Year+24%

1 Month-3%

Arbutus Biopharma Financials at a Glance

Market Cap

$817.30M

Revenue (TTM)

$14.08M

Net Income (TTM)

$33.50M

EPS (TTM)

$-0.18

P/E Ratio

-23.66

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$4.05

Volume

28,770

Open

$4.13

Price

$4.05

Volume

28,770

Open

$4.13

Previous Close

$4.15

Daily Range

$4.01 - $4.13

52-Week Range

$2.94 - $5.10

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$4.05

Volume

28,770

Open

$4.13

Previous Close

$4.15

Daily Range

$4.01 - $4.13

52-Week Range

$2.94 - $5.10

ABUS News

Tiny Arbutus Biopharma Wins Patent Litigation Fight with COVID-19 Vaccine Implications

Taylor CarmichaelJul 24, 2020

Here's Why Arbutus Biopharma Corp. Is Tanking Today

Keith SpeightsOct 9, 2018

Page 1

ABUS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Arbutus Biopharma

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Lindsay Androski, CFA, MBA

Website

www.arbutusbio.com

Headquarters

Warminster, PA 18974, US

ABUS Financials

Key Financial Metrics (TTM)

Gross Margin

36%

Operating Margin

-3%

Net Income Margin

-2%

Return on Equity

-39%

Return on Capital

-55%

Return on Assets

-35%

Earnings Yield

-4.23%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$817.30M

Shares Outstanding

196.94M

Volume

28.77K

Avg. Volume

2.42M

Financials (TTM)

Gross Profit

$13.72M

Operating Income

$27.05M

EBITDA

$26.69M

Operating Cash Flow

$39.64M

Capital Expenditure

$0.00

Free Cash Flow

$39.64M

Cash & ST Invst.

$91.47M

Total Debt

$4.19M

Arbutus Biopharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$1.05M

-33.2%

Gross Profit

$1.04M

+114.4%

Gross Margin

98.95%

N/A

Market Cap

$817.30M

N/A

Market Cap/Employee

$18.58M

N/A

Employees

N/A

Net Income

$3.76M

+70.0%

EBITDA

$7.63M

+50.2%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$87.28M

-28.1%

Accounts Receivable

$1.75M

-27.5%

Inventory

$0.00

N/A

Long Term Debt

$3.64M

+351.7%

Short Term Debt

$547.00K

+13.3%

Return on Assets

-35.41%

N/A

Return on Invested Capital

-55.42%

N/A

Free Cash Flow

$4.68M

+55.0%

Operating Cash Flow

$4.68M

+54.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

KURAKura Oncology, Inc.

KURAKura Oncology, Inc.$8.81-0.24%

SPRYARS Pharmaceuticals, Inc.

SPRYARS Pharmaceuticals, Inc.$7.77-2.14%

SVRASavara Inc.

SVRASavara Inc.$4.86-3.09%

SEPNSepterna, Inc.

SEPNSepterna, Inc.$23.15-4.69%

EYPTEyePoint Pharmaceuticals, Inc.

EYPTEyePoint Pharmaceuticals, Inc.$12.77-5.23%

PROKProKidney Corp.

PROKProKidney Corp.$1.81-0.82%

BCAXBicara Therapeutics Inc. Common Stock

BCAXBicara Therapeutics Inc. Common Stock$21.38-2.46%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$12.53+0.11%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.18+0.04%

POETPoet Technologies

POETPoet Technologies$6.42-0.20%

KALVKalVista Pharmaceuticals

KALVKalVista Pharmaceuticals$26.70+0.39%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$61.14+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$11.91-0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$11.24-0.03%

Questions About ABUS

What is the current price of Arbutus Biopharma?

Arbutus Biopharma is trading at $4.06 per share.

What is the 52-week range for Arbutus Biopharma?

Over the past 52 weeks, Arbutus Biopharma has traded between $2.94 and $5.10.

How much debt does Arbutus Biopharma have?

As of the most recent reporting period, Arbutus Biopharma reported total debt of $4.19M.

How much cash does Arbutus Biopharma have on hand?

Arbutus Biopharma reported $18.01M in cash and cash equivalents in its most recent financial results.

What is Arbutus Biopharma’s dividend yield?

Arbutus Biopharma does not currently have a dividend yield.

Arbutus Biopharma

Arbutus Biopharma Financials at a Glance

ABUS News

Arbutus (ABUS) Q2 Revenue Surges 529%

Why Arbutus Biopharma Stock Is Sinking Today

What's the Outlook for Arbutus Biopharma?

Why Arbutus Biopharma Is Rocketing Higher Today

Here's Why Arbutus Biopharma Fell Today

3 Healthcare Stocks That Rocketed Higher in July

Tiny Arbutus Biopharma Wins Patent Litigation Fight with COVID-19 Vaccine Implications

Here's Why Arbutus Biopharma Corp. Is Tanking Today

ABUS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Arbutus Biopharma

ABUS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Arbutus Biopharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ABUS

What is the current price of Arbutus Biopharma?

What is the 52-week range for Arbutus Biopharma?

How much debt does Arbutus Biopharma have?

How much cash does Arbutus Biopharma have on hand?

What is Arbutus Biopharma’s dividend yield?

Premium Investing Services